Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
about
Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children's HospitalBiological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.Molecular epidemiology of macrolide-resistant isolates of Streptococcus pneumoniae collected from blood and respiratory specimens in Norway.Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcusAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter studyIn vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanismsComparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countriesEmergence of group A streptococcus strains with different mechanisms of macrolide resistanceAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolidesRibosomal mutations in Streptococcus pneumoniae clinical isolatesEmergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Heterogeneous macrolide resistance and gene conversion in the pneumococcusMechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.Ketolides in the treatment of respiratory infections.Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.Antimicrobial susceptibility and analysis of macrolide resistance genes in Streptococcus pneumoniae isolated in HamadanSingle- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.Resistance among Streptococcus pneumoniae: Implications for drug selection.Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000.Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 studyNovel antibacterial agents for the treatment of serious Gram-positive infections.Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae.Vancomycin resistance: occurrence, mechanisms and strategies to combat it.High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniaeApplication of molecular genetic methods in macrolide, lincosamide and streptogramin resistance diagnostics and in detection of drug-resistant Mycobacterium tuberculosis.In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniaeMacrolide resistance in Streptococcus pneumoniae: Fallacy or fact?Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi.Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
P2860
Q28534411-3862467D-A617-4EB3-8CBB-8D52BD176CB7Q30251593-42AB8D0F-EC06-42E1-A1A8-550A9EB4A2F5Q33752944-4012E535-6A92-4972-9F73-23DC5D711D96Q33858998-EB831738-C9ED-47B6-815C-753F99B3C165Q33938088-13E4B442-E36A-4A38-999A-DCCC88765BFEQ33982256-3A377997-C99F-411B-A238-312F672BE8CFQ33982390-9E114A99-D762-4506-80BF-2D3629EBBCA9Q33982834-5029677F-82F5-4E25-873A-0AAE0010DB14Q33982849-0BAFE83D-2659-43F0-9D91-2885523174A1Q33987031-9768AB45-8B88-41B6-B8CC-A43BA4B41476Q34076998-0116800F-1792-496E-B7DD-EE588663B3CAQ34104600-B8158BD3-E38D-4711-9C5E-696EAC91715DQ34105521-C8369327-002B-4B5D-9109-B88720CAA405Q34107184-67FE9B3C-FF1A-403C-A04B-F7D7A8024EB9Q34107785-7D4E9AE9-B64D-4E34-8C06-F0AAC3A8127EQ34112023-5C461862-749A-4E50-B6E3-EB0205E7F281Q34112287-B400D651-25D4-4E4A-B49D-02717316A514Q34113722-8A1A611D-FA37-451A-9A71-0E338F7BC617Q34143934-617B04C6-4BD5-46E5-89F3-C84DEDF415F7Q34281970-6A8D647D-4E8E-4B78-9771-63B997D35C93Q34301657-0DBDAB61-3E14-40FE-BA0A-973337708D97Q34498620-C48CC85F-644E-4EE1-947F-91EF3609D75FQ34544732-535F49E9-00E9-41CC-B943-654FFAB527D1Q34547639-88E891E7-D99E-4CA1-9BEC-040FA2801DD3Q34558191-77099933-3618-4719-BA5C-EAA662827369Q34564481-CE398DF9-06FA-437F-82DD-FD006A963619Q34658646-1A958300-F9D4-4FEE-B57F-199D2FAF4F72Q34749258-98F7FCE0-4EE7-4164-8C9E-2ADF92686429Q35014269-7C4A7E6B-0C8B-4A5A-AC66-378DC160244FQ35014369-7675C9B6-4A4C-417C-8BE4-7A1B0C237D2DQ35073345-21B214FC-4A97-47FA-8AB6-A15A54D93333Q35103743-3E13AEAE-3122-4935-B783-AE20743B443FQ35143886-65543AC6-A607-4989-BCDE-86F269B309D9Q35647682-3614593D-A114-4DA1-97EA-EAE1EB19F34BQ36003067-B417B780-2727-4091-8D1C-4B51479ACBE2Q36071967-DDD34D45-604B-44A6-BEEB-35D95DEDF0E1Q36170473-73A0AD0C-D65B-47A9-871C-D3094EFF9AD7Q36313199-7B6B7530-E591-4811-8C5C-768A4A73263BQ36328180-29F5494C-57F9-43E6-AA0E-B29852ADF8C1Q36342239-5558AF66-E0A5-4413-8C2A-28B30726CAAF
P2860
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Two new mechanisms of macrolid ...... tern Europe and North America.
@en
Two new mechanisms of macrolid ...... tern Europe and North America.
@nl
type
label
Two new mechanisms of macrolid ...... tern Europe and North America.
@en
Two new mechanisms of macrolid ...... tern Europe and North America.
@nl
prefLabel
Two new mechanisms of macrolid ...... tern Europe and North America.
@en
Two new mechanisms of macrolid ...... tern Europe and North America.
@nl
P2093
P2860
P1476
Two new mechanisms of macrolid ...... tern Europe and North America.
@en
P2093
Appelbaum PC
Courvalin P
Depardieu F
Petitpas J
Sutcliffe J
Tait-Kamradt A
Wondrack L
P2860
P304
P356
10.1128/AAC.44.12.3395-3401.2000
P407
P577
2000-12-01T00:00:00Z